Objective: Comprehensively describe the phenotypic spectrum of sporadic fatal insomnia (sFI) to facilitate diagnosis and management of this rare and peculiar prion disorder. Methods: A survey among major prion disease reference centers in Europe identified 13 patients diagnosed with sFI in the past 20 years. We undertook a detailed analysis of clinical and histopathological features and the results of diagnostic investigations. Results: Mean age at onset was 43 years, and mean disease duration 30 months. Early clinical findings included psychiatric, sleep, and oculomotor disturbances, followed by cognitive decline and postural instability. In all tested patients, videopolysomnography demonstrated a severe reduction of total sleep time and/or a disorganized sleep. Cerebrospinal fluid (CSF) levels of proteins 14-3-3 and t-tau were unrevealing, the concentration of neurofilament light protein (NfL) was more consistently increased, and the real-time quaking-induced conversion assay (RT-QuIC) revealed a positive prion seeding activity in 60% of cases. Electroencephalography and magnetic resonance imaging showed nonspecific findings, whereas fluorodeoxyglucose positron emission tomography (FDG-PET) demonstrated a profound bilateral thalamic hypometabolism in 71% of cases. Molecular analyses revealed PrP Sc type 2 and methionine homozygosity at PRNP codon 129 in all cases. Interpretation: sFI is a disease of young or middle-aged adults, which is difficult to reconcile with the hypothesis of a spontaneous etiology related to stochastic, age-related PrP misfolding. The combination of psychiatric and/or sleeprelated symptoms with oculomotor abnormalities represents an early peculiar clinical feature of sFI to be valued in the differential diagnosis. Video-polysomnography, FDG-PET, and especially CSF prion RT-QuIC and NfL constitute the most promising supportive diagnostic tests in vivo.
H uman prion diseases are rapidly progressive neurodegenerative disorders pathogenically related to structural changes of the cellular prion protein (PrP c ). In prion disease, PrP c converts to a beta-sheet-rich, partially protease-resistant form, termed PrP Sc , which accumulates in the brain and other tissues. Prion diseases uniquely occur in inherited, sporadic, or acquired forms and show a broad clinical and pathological heterogeneity. Four major phenotypic entities are recognized in humans, namely, Creutzfeldt-Jakob disease (CJD), Gerstmann-Sträussler-Scheinker syndrome, fatal insomnia (FI), and variably protease-sensitive prionopathy. [1] [2] [3] The phenotypic spectrum of CJD, by far the most common form, largely correlates at the molecular level with 2 major PrP Sc types with distinct physicochemical properties, designated as types 1 and 2. Moreover, the genotype at the polymorphic methionine/valine (M/V) codon 129 of the prion protein gene (PRNP) also plays a role. Accordingly, the current classification of sporadic CJD (sCJD) recognizes 6 major subtypes largely corresponding to all possible combinations of the 2 molecular variables (eg, MM1, MM2, VV1, VV2, etc). 4, 5 The most significant exception is the MM2 group, which includes 2 subtypes designated as MM2-cortical (MM2C) and MM2-thalamic (MM2T) based on distinctive pathological features. 4 Given its striking clinical and neuropathologic similarities with fatal familial insomnia (FFI), a genetic prion disease linked to a point mutation at codon 178 (D178N) in the PRNP coupled with methionine at codon 129, the MM2T subtype is also known as sporadic FI (sFI). 6, 7 Transmission studies using susceptible transgenic mice have consistently demonstrated that the same prion strain is associated with both sFI and FFI. 8, 9 In contrast to what has been the rule for the most common neurodegenerative disorders, sFI is rarer than its genetic counterpart. 10 Whereas the recognized patients with FFI are numerous and belong to >50 families worldwide, only about 30 cases of CJD MM2T and a few cases with mixed MM2T and MM2C features (MM2T+C) have been recorded to date. 6, 8, 9, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] Moreover, whereas the first description of FFI dates back to 1986 and its recognition as a genetic prion disease to 1992, the characterization of sFI as a distinct sporadic prion disease subtype was only achieved in 1999. 6, 8 It is noteworthy, however, that a few cases previously reported under the terms thalamic dementia, thalamic degeneration, or thalamic form of CJD, either sporadic or familial, likely belonged to the same disease entity. 1, [24] [25] [26] [27] [28] [29] [30] [31] [32] Here, we describe in detail the clinical findings, results of diagnostic investigations, and neuropathological features of the largest series of sFI patients reported to date, representing the result of 20 years of prion disease surveillance in Europe.
Patients and Methods

Patient Selection
After inquiry to the majority of European CJD reference centers, we identified 13 cases of sCJD MM2T or sFI, which were diagnosed in Italy (n = 7, Patients 1-6 and Patient 13), the Netherlands (n = 1, Patient 7), Spain (n = 1, Patient 8), United Kingdom (n = 2, Patients 9 and 10), and Germany (n = 2, patients 11 and 12) over the past 20 years. Reference laboratories for CJD in France, Austria, Poland, Belgium, and Denmark did not report any case. A single sCJD MM2T+C, recently reported in Spain, 23 was not included in the present series.
The diagnosis of sCJD MM2T was formulated postmortem, according to neuropathologic consensus criteria 
Clinical Data and Diagnostic Investigations
For each patient, we collected and reviewed data regarding clinical history, neurological examination, and the specific evaluation of cognitive status, which in the majority of cases included neuropsychological batteries.
We also reviewed copies and collected data concerning electroencephalographic (EEG) recordings (n = 13), videopolysomnography (n = 4) or long-term video-EEG (n = 1), autonomic function tests (n = 6), neurohormonal assays (n = 3), brain magnetic resonance imaging (MRI; n = 13), FDG-PET (n = 7), and Tc 99m hexamethyl propylene amine oxime (HMPAO) or ethyl cysteinate dimer (ECD) cerebral blood flow (CBF) single photon emission computed tomography (SPECT; n = 3). EEG and MRI findings were classified according to established criteria. 34, 35 The most abnormal result on record was considered in cases with serial EEG or neuroimaging examinations.
In the absence of a standardized protocol, MRI scans variably included T1/T2-weighted scans (n = 13), fluidattenuated inversion recovery (FLAIR) sequences (n = 11), diffusion-weighted imaging (DWI; n = 11), and/or H 1 -spectroscopy (n = 3).
Video-polysomnographies, tests of autonomic function, neurohormonal assays, brain FDG-PET, and CBF-SPECT were performed at the notifying hospitals according to standard procedures.
CSF biomarker analyses included proteins 14-3-3 (n = 12), total (t)-tau (n = 10), neurofilament light chain (NfL, n = 3), and prion seeding activity (n = 5). The 14-3-3 protein was measured semiquantitatively by immunoblotting, whereas t-tau and NfL proteins were quantitatively analyzed using commercially available kits based on a sandwich enzyme-linked immunosorbent assay method, as described. 36, 37 Prion seeding activity was assessed by RT-QuIC as previously described. 40 We also carried out a semiquantitative evaluation of spongiform change by comparing H&E-stained sections obtained from 8 brain regions. We scored the spongiform change as absent, mild, moderate, severe, or status spongiosus.
Furthermore, we determined the type and relative amount of PrP Sc on 10% brain homogenates, after treatment with proteinase K, according to established consensus protocols. 41 Patients 1, 5, and 6 were briefly described in previous studies. 9, 16 We conducted the study according to the revised Declaration of Helsinki and Good Clinical Practice guidelines. The protocol for this study received prior approval by the Institute of Neurological Sciences of Bologna Institutional Review Board. Informed consent was obtained from each subject or next of kin.
Results
Demographic and Clinical Features
The mean age at symptom onset was 43 years (range = 24-80), and the mean duration of clinical disease was 30 months (range = 7-96; Table 1 ).
Family history was unremarkable except for Patient 1 who, despite nonmutated carrier status, belonged to a large kindred with several FFI affected members, as previously described. 16 Prominent clinical manifestations at onset included psychiatric, sleep, and oculomotor/visual disturbances (Fig 1) . Among the former, the most frequent symptoms included mood alterations (n = 11 patients, 84.6%), behavioral and personality changes (n = 7, 53.8%), delusions (n = 7, 53.8%), and hallucinations (n = 2, 15.4%). Eleven patients (84.6%) complained of sleep disturbances, including drugresistant insomnia (n = 10, 76.9%), simple or complex movements during sleep (n = 7, 53.8%), daytime sleepiness (n = 5, 38.5%), and sleep vocalizations (n = 3, 23.1%). Moreover, oculomotor dysfunction and/or gaze palsy affected 11 (84.6%) patients, causing diplopia in 7 (53.8%).
In the full-blown disease, all subjects developed progressive cognitive impairment and postural instability associated with retro-/lateropulsion and gait disturbances, whereas only some suffered additional motor abnormalities. Specifically, based on the results of consecutive neurological evaluations and of administered neuropsychological batteries, the most affected cognitive domains included memory (12/12, 100%), temporal and/or spatial orientation (9/12, 75.0%), language (9/12, 75.0%), executive functions (9/12, 75.0%), and attention (7/12, 58.3%). Moreover, 5 of 12 (41.7%) patients had agnosia, 4 of 12 (33.3%) had apraxia, and 4 of 12 (33.3%) visuospatial deficits.
Typical motor features were dysarthria (n = 12, 92.3%), cerebellar signs (n = 10, 76.9%), pyramidal signs (n = 10, 76.9%), myoclonus (n = 10, 76.9%), diurnalnocturnal motor hyperactivity (n = 8, 61.5%), and extrapyramidal signs (n = 13, 100%). The latter comprised a hypokinetic-rigid syndrome in 12 patients (92.3%), hyperkinetic involuntary movements (mainly chorea) in 4 (30.8%), and limb dystonia in 4 (30.8%).
Finally, 5 (38.5%) patients showed signs of autonomic hyperactivity, such as systemic hypertension (often drug-resistant; n = 3, 23.1%), mild pyrexia (n = 3, 23.1%), hyperhidrosis (n = 3, 23.1%), neurogenic urinary alterations (n = 3, 23.1%), tachycardia (n = 2, 15.3%), and constipation (n = 2, 15.3%). In addition, significant weight loss was reported in 5 cases (38.4%; see Table 1 ). Seven patients (53.8%) evolved to akinetic mutism, although this may not reliably represent the real frequency of this condition given that some medical reports contained only scanty information about the terminal disease stage (see Fig 1) .
Results of Diagnostic Investigations CSF Biomarkers. The 14-3-3 assay was negative in all examined cases; t-tau was within normal levels in 7 cases, even when repeated at different clinical stages (Patients 5, 12, and 13), moderately increased in 1 (Patient 1), and increased at a level compatible with a diagnosis of probable CJD in only 1 case (Patient 2; Table 2 ). Finally, RTQuIC was positive in 3 of 5 examined cases. In all tested patients, NfL levels were significantly higher than in healthy controls and other dementia groups as previously described. 37 Genetic Analysis. All cases were methionine homozygous at codon 129 (129M/M). The presence of the D178N mutation linked to FFI or any other PRNP mutation was excluded in 12 of 13 patients by direct sequencing. EEG and Video-Polysomnography. EEG recordings were either normal (n = 2, 15.4%; Cases 10 and 11) or showed a slow background activity characterized by dominant theta-delta rhythm (n = 11, 84.6%). Periodic sharp-wave complexes (PSWC) were seen in only 1 of 13 patients (7.7%; Case 2) in a late recording performed 1 month before death. Video-polysomnographic evaluation or long-term video-EEG monitoring (Cases 1, 2, 3, 8, and 13) demonstrated a severe reduction of total sleep time and/or a completely disorganized sleep architecture and microstructure in tested patients. Specifically, in 4 of 5 of them (80%; Cases 1, 2, 3, and 13), wakefulness appeared to interchangeably alternate with subwakefulness (N1 sleep stage, light stupor) and occasionally with brief recurrent episodes of rapid eye movement (REM) sleep while K-complexes, spindles, and delta sleep, which are the hallmarks of non-REM sleep stages N2 and N3, were severely reduced or suppressed. A reduction of total sleep time was also documented in the fifth case (20%; Patient 8), although detailed information about sleep microstructure was not available in this case. Hypnic disruption until complete loss of physiological sleep seemed to occur progressively in sFI, as documented by serial polysomnographic recordings in Patient 1 (Fig 2) . Moreover, episodes of oneiric stupor, a complex motor behavior arising from subwakefulness, characterized by occurrence of stereotyped gestures mimicking daily-life activities, were documented in 2 cases (40%; Cases 1 and 13; Supplementary Video). Finally, in 1 patient (20%; Patient 2), polysomnographic recording revealed a severe disruption of sleep architecture and microstructure even in the absence of any subjective complaint of sleep disturbance.
Autonomic Function and Neurohormonal Tests. Autonomic function and neurohormonal tests were performed in all 5 cases manifesting signs of autonomic overactivity (Cases 1, 3, 6, 9, and 13) and in an additional patient (Case 8) lacking them ( Table 3) . The results showed sympathetic hyperactivity in 1 patient (16.7%; Case 1), drug-resistant systemic hypertension in another patient (16.7%; Case 6), and absence of significant abnormalities in the other 4 (66.6%).
Neuroimaging. Single or consecutive MRI examinations were unremarkable in 5 patients (38.5%; Cases 4, 8, 9, 11, and 13). In all the others, brain MRI showed, mainly in the late disease stages, a mild to moderate atrophy of the brain (n = 8, 61.5%; Cases 1, 2, 3, 5, 6, 7, 10, and 12), cerebellum (n = 3, 23.1%; Cases 3, 5, and 6), and/or the brainstem at the level of inferior olives and pons (n = 1, 7.7%; Case 5). Cortical hyperintensities were observed in only 1 (9.1%; Case 1) of 11 patients who underwent DWI and/or FLAIR sequences (Fig 3A) . Finally, a nonspecific leukoencephalopathy was reported in 1 patient (9.1%; Case 6).
Brain spectroscopy MRI showed metabolic alterations compatible with thalamic and cortical neurodegeneration in 1 case (Patient 1), whereas it was unremarkable in 2 other cases (Patients 3 and 13) .
FDG-PET studies revealed a pronounced bilateral thalamic hypometabolism and scattered hypometabolic cortical areas (see Fig 3B, C) in 5 of 7 patients (71.4%; Cases 1, 3, 5, 6, and 13), whereas they were unremarkable in 2 (28.6%; Patients 7 and 8).
Furthermore, 99mTc-HMPAO or ECD-SPECT scans showed abnormal cortical perfusion, but no thalamic alterations in 2 of 3 patients (66.7%; Case 2 and 7), while cortical perfusion was unremarkable in 1 case (33.3%; Case 8).
Neuropathological Findings
All brains of 12 definite cases fulfilled the consensus criteria for the histopathological diagnosis of sCJD MM2T 33 (Table 4 and Fig 4) . Overall, the results confirmed the very distinctive traits that define the sCJD MM2T histotype, although they also showed a few novel features. All cases demonstrated a moderate to severe neuronal loss and astrogliosis in the mediodorsal and anterior nuclei of the thalamus and in the inferior olivary nuclei but a relative sparing of striatum and hippocampus (cornu ammonis and subiculum). Moreover, all showed a moderate Bergmann gliosis and torpedo formation in the cerebellum and most had a mild to moderate patchy spongiform change in the cerebral cortex. As previously shown in FFI, 42, 43 disease duration significantly affected the spread and severity of histopathology. Accordingly, the 2 cases with moderate atrophy and most focally distributed changes in the thalamus had the shortest disease duration, whereas those with the most severe thalamic degeneration, extending beyond the most affected nuclei listed above, had the longest course. Furthermore, whereas the 2 cases with the shortest duration of symptoms (7 and 8 months) only showed patchy, mild foci of spongiform change in the cerebral cortex with only mild neurodegenerative changes, the histopathological changes progressed to status spongiosus and severe atrophy in the two cases with the longest course (54 and 96 months). Moreover, the striatum was relatively unaffected in the cases with the shortest course, but florid spongiform change was observed in the case with the longest duration, although with limited associated neuronal loss. Finally, in a subgroup of cases with sufficient available material (7/12 patients; see Table 4 ), the hypothalamus showed focal pathology characterized by mild to moderate astrogliosis, as previously described in FFI. 42, 43 PrP immunohistochemistry revealed some new features, possibly related to disease duration. Although most cases only had a patchy PrP positivity of synaptic (not shown) or small granular type mostly in the superficial layer of the cerebral cortex (see Fig 4K) , 1 of the 2 patients with the longest course demonstrated sparse, small plaquelike deposits in the cerebral cortex (see Fig 4L) . PrP Sc typing by Western blot analyses confirmed the presence of type 2 in all definite cases (see Fig 4M) . As previously shown, 6 PrP Sc was characterized, at variance with FFI, by a predominant monoglycosylated form and the lack of underrepresentation of the unglycosylated isoform.
Discussion
We have described clinical findings, results of diagnostic investigations, and neuropathological features of the largest series of sFI patients reported to date, reflecting the results of about 20 years of prion disease surveillance in Europe. The results expand the phenotypic spectrum of the disease and provide an update on the clinical impact of current available diagnostic investigations. Age at onset (mean = 43 years) in the present series was even younger than previously reported in sFI cases (mean = 46 years) or in FFI patients carrying MM at codon 129 (mean = 51 years) and significantly younger than in typical sCJD patients (mean = 67 years). [6] [7] [8] [9] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [44] [45] [46] The result confirms that sFI is a disease of young or middle-aged adults rather than of the elderly, which is intriguing because this is difficult to reconcile with the current leading hypothesis of a "stochastic" origin of sporadic prion disease increasing with age. 20 Furthermore, the comparable or even earlier onset of sFI cases in comparison to FFI subjects indicates that age at onset in FFI, and possibly other genetic prion diseases, mainly depends on the specific prion strain (ie, M2T) rather than on the presence of the PRNP mutation, as commonly believed. The disease duration (mean = 30 months) in our series largely overlapped with that previously reported in sFI (mean = 26 months) and was, therefore, significantly longer than that of FFI carrying MM at codon 129 (about 10 months). [6] [7] [8] [9] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [44] [45] [46] Notably, one of the patients reported here had one of the longest clinical courses reported to date in sporadic human prion disease (Patient 11, 96 months). 44 Regarding clinical manifestations, a significant and novel finding was the presence of psychiatric symptoms and a cognitive impairment, involving mainly memory, spatial and temporal orientation, language, executive functions, and attention in all patients during the early or middle disease stages, which is more consistent with CJD than FFI. 20 According to previous reports, FFI patients, especially those MM homozygous at codon ACTH = adrenocorticotropic hormone; BcT = body core temperature; BP = blood pressure; FSH = follicle-stimulating hormone; HR = heart rate; LH = luteinizing hormone; mo = months; PRL = prolactin; SSR = sympathetic skin response.
129, develop early progressive impairment of attention, vigilance, and memory, resembling a progressive confusional state, but general intelligence and symbolic functions remain substantially intact until late in the disease course. 7, 45, 47 Besides cognitive impairment, the clinical sFI phenotype invariably comprises oculomotor and gait disturbances, dysarthria, myoclonus, and extrapyramidal, cerebellar, and pyramidal signs. 7, 20 Among them, the most distinctive are the oculomotor dysfunction leading to early diplopia and the postural instability with latero-/retropulsion and gait impairment. The latter is alike that previously reported in FFI heterozygotes at codon 129, and thought to be related to thalamic degeneration leading, directly or indirectly, to frontal cortical dysfunction. 46 Previously, the peculiar sleep and autonomic disturbances described in FFI were referred to as "agrypnia excitata" syndrome, whose distinctive features are severe loss of sleep and persistent motor and sympathetic overactivity. 7, 48, 49 In our patient population of sFI, insomnia was an early and prominent manifestation in 10 cases, whereas sympathetic and motor overactivity was less common. However, as previously remarked in FI, 20 in the absence of a spontaneous subjective complaint, sleep and autonomic symptoms may go unnoticed unless an accurate clinical history and videopolysomnographic and autonomic evaluation are obtained. This was particularly evident in Patient 2, in whom the sleep disturbances were discovered at neurophysiological evaluation despite this not being reported by the patient. In virtually all patients in whom videopolysomnography was performed, we found a severe reduction of total sleep time and/or completely disorganized sleep with absence of the physiological polygrapic features of non-REM sleep stages N2 and N3 (spindles, K-complexes, and delta waves). 7, 45, 48 Moreover, in 2 cases we documented episodes of oneiric stupor, a behavioral state observed in agrypnia excitata, characterized by the recurrence of stereotyped and repetitive gestures mimicking the content of dreams (often referring to ordinary daily-life activities), and typically arising from subwakefulness (N1 stage). 48, 49 The present study provides, for the first time, the results of neurophysiological and biochemical evaluations of autonomic function in sFI patients. Multiple tests revealed the presence of sympathetic hyperactivity in only 1 of the cases with clinically reported autonomic signs. Although this discrepancy may also be attributed to the relative low sensitivity of the tests performed, or perhaps to interlaboratory variability, taken together, our findings indicate that the clinical phenotype in patients with sFI better match that of the FFI MV heterozygotes at PRNP codon 129, which notoriously manifest less prominent sleep and autonomic disturbances than the MM homozygotes. 7, 45, 46 The diagnosis of sFI may be very difficult because of the low sensitivity of currently established investigations on which the criteria for probable sCJD are based. 35 EEG, brain MRI, and CSF 14-3-3 were all unrevealing in our cohort. Specifically, 14-3-3 was negative in all of our cases, consistent with previous reports. 6, 9, 11, 13, 15, 17, 18, 20, 22 Moreover, only 2 patients had EEG PSWC or MRI cortical hyperintensities suggestive of a diagnosis of probable CJD. Previously, DWI/diffusion tensor imaging cortical hyperintensities were documented only in mixed MM2T +2C cases. 13, 19, 23 Prion RT-QuIC showed only 60% sensitivity for the MM2T subtype, which was similar to that reported in other sCJD subtypes linked to abnormal prion protein PrP Sc type 2 and the MM codon 129 genotype. 36, 38 In contrast, in all cases who underwent CSF NfL analysis, we documented high values for this biomarker. 37 Therefore, we recommend the use of both CSF prion RT-QuIC and NfL assays based on their high specificity and sensitivity, respectively. Furthermore, 71.4% of subjects who underwent a brain FDG-PET study showed significant bilateral hypometabolism in the thalamus in association with variable cortical involvement. These findings confirm the usefulness of FDG-PET in the diagnosis of the FI phenotype as previously reported. 8, 13, 20, 50 In all definite cases, neuropathological assessment revealed moderate to severe neuronal loss of the anterior medial thalamus and inferior olives with a variable degree of cortical spongiform change reflecting disease duration, as previously described. 6 Other typical features of this subtype were the absence of spongiform change in the cerebellum, despite the significant gliosis and torpedo formation, and the relative sparing of striatal nuclei (ie, caudate and putamen). The patient with the shortest duration, Case 2, showed only moderate neuronal loss in the thalamus and in the olives, whereas in one of the cases with the longest duration (ie, Case 7), immunostaining revealed a plaque-like deposition in the cerebral cortex, cerebellum, and striatum, as previously reported. 12, 14, 21, 22 This difference is consistent with the evidence from FFI brains that the amount of prion protein deposition in the cortex and the degree of cortical pathology strongly depend on disease duration. 42, 43 In conclusion, we have contributed the largest study to date on the clinicopathological features and results of diagnostic investigations in sFI and the first report on the results of the epidemiologic surveillance of sFI in Europe. We have shown that, at variance with FFI homozygotes, in sFI patients insomnia and other sleep abnormalities are usually accompanied by cognitive, psychiatric, and motor disturbances. Furthermore, we have defined the neuropsychological profile of sFI for the first time, and have demonstrated a low prevalence of autonomic and neurohormonal alterations, as confirmed by multiple diagnostic investigations. The absence of pathognomonic clinical signs, the young age at onset, and the relatively low sensitivity of classical diagnostic investigations (EEG, MRI, CSF 14-3-3, and t-tau) make the clinical diagnosis of sFI challenging. However, our results indicate that video-polysomnography, brain FDG-PET, and especially CSF prion RT-QuIC and CSF NfL are the most promising diagnostic tests in vivo.
